Minster Pharmaceuticals
Our Therapeutic Focus
Migraines
For some they are frustrating and infrequent, but for others they are a daily experience with a major negative impact on the quality of life.......
For some they are frustrating and infrequent, but for others they are a daily experience with a major negative impact on the quality of life.......
.gif "Minster - Minster - Read More"){kind=small}
Schizophrenia
Is a major psychiatric disease which affects millions. Management of progressive cognitive decline is recognised as a major unmet need.. ...
Is a major psychiatric disease which affects millions. Management of progressive cognitive decline is recognised as a major unmet need.. ...
Our Products
.gif "Minster - Minster - Home Page Thumb")
Tonabersat
Is from a new selective class of drugs called neuronal gap junction blockers, with real potential in the prevention of migraine...
Is from a new selective class of drugs called neuronal gap junction blockers, with real potential in the prevention of migraine...
.gif "Minster - Minster - Home Page Thumb"){kind=small}
Sabcomeline
Offering a new approach to the treatment of cognitive decline in schizophrenia...
Offering a new approach to the treatment of cognitive decline in schizophrenia...
News and features
30 June 2008
Tonabersat highlighted at AHS Symposium
Tonabersat highlighted at AHS Symposium
Minster is pleased to announce that, Professor David W Dodick, MD Dept of Neurology, Mayo Clinic, Scottsdale, gave a presentation - Gap Junction Blockers: Targeting Migraine Prevention, at a satellite symposium at the AHS’s 50th Meeting
16 June 2008
Minster Pharmaceuticals plc (AIM: MPM), is pleased to announce that its Phase IIb TEMPUS study is now fully enrolled.